Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Fiche publication

Date publication

février 2018

Journal

Gut

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28053054

Résumé

Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab.